Last reviewed · How we verify
Fluticasone Evohaler pMDI
Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release.
Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Fluticasone Evohaler pMDI |
|---|---|
| Sponsor | University of Dundee |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent inhaled corticosteroid that acts as a glucocorticoid receptor agonist in the lungs. It suppresses the production and release of inflammatory cytokines, chemokines, and adhesion molecules, reducing airway inflammation, mucus production, and bronchial hyperresponsiveness. The Evohaler pMDI (pressurized metered-dose inhaler) formulation delivers the drug directly to the airways for local anti-inflammatory effects.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia
- Tremor
- Headache
- Palpitations
Key clinical trials
- Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate (PHASE1)
- Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis (PHASE4)
- A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer (PHASE1)
- Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma (PHASE2)
- Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block (PHASE1)
- Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block (PHASE1)
- Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients (PHASE3)
- Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Evohaler pMDI CI brief — competitive landscape report
- Fluticasone Evohaler pMDI updates RSS · CI watch RSS
- University of Dundee portfolio CI